NCT03217721 (REANEUF) is a clinical trial in Neutropenia, Febrile, sponsored by University Hospital, Brest.

Who is sponsoring NCT03217721?

NCT03217721 is sponsored by University Hospital, Brest.

What condition does NCT03217721 study?

NCT03217721 studies Neutropenia, Febrile.

Is NCT03217721 still recruiting?

NCT03217721 is currently completed. Last updated 12 August 2024.

Last reviewed 2024-08-12 · How we verify

NCT03217721: REANEUF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antibiotics Management of Septic Neutropenic Patients in the Intensive Care Unit

Completed Last updated 12 August 2024

What this trial tests

trial in Neutropenia, Febrile in 130 participants. Completed in 19 September 2017.

Timeline

19 June 2017

Primary endpoint
19 September 2017

19 September 2017

Quick facts

Lead sponsor	University Hospital, Brest
Status	Completed
Study type	OBSERVATIONAL
Enrollment	130
Start date	19 June 2017
Primary completion	19 September 2017
Estimated completion	19 September 2017
Sites	1 location across France

Conditions studied

Neutropenia, Febrile — all drugs for Neutropenia, Febrile →

Sponsor

University Hospital, Brest

Who can join

Eligibility, any sex, with Neutropenia, Febrile. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neutropenia, defined by an absolute count of polymorphonuclear neutrophils less than \<1500/mm3, exposes patients to infectious complications that can lead to sepsis or septic shock. The mortality risk is higher risk. The recommendations published in 2016 were formulated to homogenize the clinical practices to improve the survival.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Proceedings of Réanimation 2018, the French Intensive Care Society International Congress.
· 2018 · cited 6× · PMID 29404789 · DOI 10.1186/s13613-017-0345-7

Verify or expand the search:

Other University Hospital, Brest trials

Trials by the same sponsor.

NCT07526688 — Aerobic Physical Activity and Orofacial Myofascial Pain · NA · not yet recruiting
NCT07487155 — Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Dis · NA · not yet recruiting
NCT07417605 — Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiatio · not yet recruiting
NCT07302074 — Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations a · NA · recruiting
NCT06441773 — Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated W · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03217721 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Brest
Last refreshed: 12 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03217721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing